| Literature DB >> 32404351 |
Kai Wang1,2, Xiaozhen Dai3, Junhong He2,4, Xiaoqing Yan4, Chengkui Yang2, Xia Fan4, Shiyue Sun4, Jing Chen2, Jianxiang Xu2, Zhongbin Deng5, Jiawei Fan3, Xiaohuan Yuan2,6, Hairong Liu7, Edward C Carlson8, Feixia Shen1, Kupper A Wintergerst2,9,10, Daniel J Conklin5,11, Paul N Epstein2,10, Chaosheng Lu1, Yi Tan12,10.
Abstract
Diabetes-induced oxidative stress is one of the major contributors to dysfunction of endothelial progenitor cells (EPCs) and impaired endothelial regeneration. Thus, we tested whether increasing antioxidant protein metallothionein (MT) in EPCs promotes angiogenesis in a hind limb ischemia (HLI) model in endothelial MT transgenic (JTMT) mice with high-fat diet- and streptozocin-induced diabetes. Compared with littermate wild-type (WT) diabetic mice, JTMT diabetic mice had improved blood flow recovery and angiogenesis after HLI. Similarly, transplantation of JTMT bone marrow-derived mononuclear cells (BM-MNCs) stimulated greater blood flow recovery in db/db mice with HLI than did WT BM-MNCs. The improved recovery was associated with augmented EPC mobilization and angiogenic function. Further, cultured EPCs from patients with diabetes exhibited decreased MT expression, increased cell apoptosis, and impaired tube formation, while cultured JTMT EPCs had enhanced cell survival, migration, and tube formation in hypoxic/hyperglycemic conditions compared with WT EPCs. Mechanistically, MT overexpression enhanced hypoxia-inducible factor 1α (HIF-1α), stromal cell-derived factor (SDF-1), and vascular endothelial growth factor (VEGF) expression and reduced oxidative stress in ischemic tissues. MT's pro-EPC effects were abrogated by siRNA knockdown of HIF-1α without affecting its antioxidant action. These results indicate that endothelial MT overexpression is sufficient to protect against diabetes-induced impairment of angiogenesis by promoting EPC function, most likely through upregulation of HIF-1α/SDF-1/VEGF signaling and reducing oxidative stress.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32404351 PMCID: PMC7519474 DOI: 10.2337/db19-0829
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461